 Collaborators.
Am J Surg 1998;176:172-5.
464. Beitner H, Hammar H, Olsson AG, Thyresson N. Prostaglandin E1
treatment of leg ulcers caused by venous or arterial incompetence.
Acta Derm Venereol 1980;60:425-30.
465. Rudofsky G. Intravenous prostaglandin E1 in the treatment of venous
ulcersda double-blind, placebo-controlled trial. Vasa Suppl 1989;28:
39-43.
466. Milio G, Mina C, Cospite V, Almasio PL, Novo S. Efﬁcacy of the
treatment with prostaglandin E-1 in venous ulcers of the lower limbs.
J Vasc Surg 2005;42:304-8.
467. Coleridge Smith PD, Thomas P, Scurr JH, Dormandy JA. Causes of
venous ulceration: A new hypothesis. Br Med J (Clin Res Ed)
1988;296:1726-7.
468. Lyseng-Williamson KA, Perry CM. Micronised puriﬁed ﬂavonoid
fraction: A review of its use in chronic venous insufﬁciency, venous
ulcers and haemorrhoids. Drugs 2003;63:71-100.
469. Guilhou JJ, Dereure O, Marzin L, Ouvry P, Zuccarelli F,
Debure C, et al. Efﬁcacy of Daﬂon 500 mg in venous leg ulcer

58S O’Donnell et al

healing: A double-blind, randomized, controlled versus placebo
trial in 107 patients. Angiology 1997;48:77-85.
470. Coleridge-Smith P, Lok C, Ramelet AA. Venous leg ulcer: A metaanalysis of adjunctive therapy with micronized puriﬁed ﬂavonoid
fraction. Eur J Vasc Endovasc Surg